Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna [Yahoo! Finance]
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Carisma Therapeutics' solid tumour therapy obtains FDA Fast Track status [Yahoo! Finance]
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors [Yahoo! Finance]